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LETTERS TO THE EDITORRegarding “Failure modes of thoracic endografts:
Prevention and management”
In the article by Lee1 describing the failure modes of current
thoracic endografts, the author states that the TAG endograft
(W. L. Gore and Associates, Flagstaff, Ariz) may retract during
deployment because the device is released from the middle portion
to the ends. He claims that this event is more evident in tortuous
aortas and when long endografts are used. He further contends
that this foreshortening of the device may be related to the first
point of contact or fixation during deployment, which may be in
the middle of the aneurysm sac.
In our experience with the endovascular repair of thoracic
aortic aneurysms and type B dissections, we have not seen this
phenomenon. Conversely, and as indicated by Lee, if the TAG
endograft is deployed while it is fixed against the outer curve of the
arch over a superstiff guidewire, the deployment is quite accurate.
Such deployment accuracy and lack of “retraction” upon expan-
sion are actually the main advantages of the TAG device as minimal
device displacement or movement during deployment occurs be-
cause of the simple and smooth single-step mechanism of en-
dograft release. In contradistinction to other devices, particularly
those with a pin-pull method of unsheathing, the TAG endograft
ease of deployment results in improved control and predictability
of positioning, even in cases of severe tortuosity.
Of note, the stability of the deployment does depend on the
fixation of the endograft along the outer curve of the thoracic
aorta, particularly at the level of the arch. Such positioning does
not occur naturally and is usually attained when the superstiff
guidewire is advanced and looped in the ascending aorta against
the aortic valve. Under these circumstances, the TAG device is
pinned over the stiff portion of the guidewire along the outer curve
of the arch and fixed to the proximal and distal landing zones.
Contrary to Lee’s assertion, the TAG device is usually released with
minimal or no point of contact or fixation in the middle of the
aneurysm sac, which is rarely in contact with the stiff guidewire or
the endograft during deployment inmost fusiform aneurysms. The
need of using the shortest TAG device and/or a second endograft
to improve deployment accuracy is therefore totally unfounded.
Carlos H. Timaran, MD
University of Texas Southwestern Medical Center
Dallas, Tex
Michael D. Dake, MD
Stanford University Medical Center
Stanford, Calif
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Reply
Thank you for the comments and useful technical tips. The
TAG (W. L. Gore and Associates, Flagstaff, Ariz) endograft has
many positive attributes. It has a good track record for being a safe
and effective device for the treatment of thoracic aortic aneurysms
and has provided lifesaving treatment to thousands of patients who
would otherwise have had to face the natural history of their aortic
diseases.Although every device may be susceptible to one or more
failures, certain aspects of a device’s construction, delivery system,
or method of deployment may make one device more prone to one
type of failure over another. Most of these adverse events are
fortunately extremely rare, which is a validation of the rigorous
premarket testing and approval process of these types of medical
devices.
Certain maneuvers such as pinning the device against the
outer curve clearly do help in stabilization of the device during
deployment, but the issues described in this article represent ob-
servations made from an aggregate experience of 400 deploy-
ments in nearly 250 patients. Inmost cases, the complications were
in part related to a constellation of unusual anatomies and pathol-
ogies, many of which were outside the manufacturer’s instructions
for use (IFU). Thus, operators should be encouraged to stay within
the IFU. We should keep in mind that the guidelines were written
for a purpose. In the final analysis, the reader is reminded that,
“[device] failure is an equal opportunity hazard.”
W. Anthony Lee, MD
Division of Vascular Surgery
University of Florida
Gainesville, Fla
doi:10.1016/j.jvs.2009.05.007
Regarding “Brain and spinal cord protection during
simultaneous aortic arch and thoracoabdominal
aneurysm repair”
We read with great interest the recently published article by
Mommertz et al1 and we congratulate the authors for the excellent
clinical results in such surgical-challenging cases.
In 1999, Biglioli et al2 proposed the “quick, simple clamping
technique” for the replacement of the descending thoracic aorta to
prevent spinal cord injury. They showed that by maintaining total
aortic cross-clamping time under the crucial 25 minutes with this
particular technique, the probability of spinal cord injury is practi-
cally eliminated; while in the subgroups of patients treated with
“left heart bypass” and “simple clamping technique”, spinal cord
injury varied from 4.5% to 14.3%, respectively. In that study, they
demonstrated that the aortic cross-clamping time is the most
important factor correlated to spinal cord injury. Many other
authors3 found that spinal cord ischemic time 30 minutes has
been considered a critical event, regardless of the spinal cord
protective techniques employed, and all spinal cord protective
approaches, including deep hypothermia and circulatory arrest,
intercostal artery reimplantation, cerebrospinal fluid drainage, dis-
tal circulatory support, or left heart bypass, could not completely
eliminate the occurrence of paraplegia.4
In the article by Mommertz et al,1 there is absolutely no
mention of the importance of total aortic clamping time and the
authors give no information regarding mean aortic clamping time
and range in their cases. On the contrary, they described in detail
other spinal cord protective strategies they used, like moderate
hypothermia, motor-evoked potentials monitoring, cerebrospinal
fluid drainage, intercostal arteries reimplanted, and left heart by-
pass. As they report, nil spinal cord injury rates, even if the numbers
are limited due to the rarity of the disease, would be of great
interest to have some information regarding aortic clamping time
in this series. It would be even more interesting to have some
information regarding the aortic clamping time in the 220 thoracic
aortic procedures they performed in the same 6-year period, and to
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ated with spinal cord injury in a multivariate regression analysis
model, independently of the combination of other protective
strategies.
Ilias Dalainas, MD, PhD
Efthimios D. Avgerinos, MD, PhD
Attikon University Hospital
Department of Vascular Surgery
University of Athens – Medical School
Athens, Greece
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The publication of Biglioli et al1 comprises patients with
descending thoracic aneurysms and the very short clamping times
indicate the limited extent of the aneurysms in a substantial num-
ber of patients. Aortic arch arteries at the proximal site or visceral
arteries at the distal site were not involved in the aneurysm. The
majority of these aneurysms would currently be treated by means
of endovascular techniques.
The pathology of patients in our publication is entirely differ-
ent and, therefore, not comparable. The aortic pathology included
the aortic arch, descending aorta, and/or the abdominal aorta,
affecting supra-aortic, visceral, and renal arteries. Total aortic
clamp times in these extensive repairs exceed many hours and
would not be tolerated without extracorporeal circulation. There-
fore, we did not consider aortic clamp times as an important
parameter.
Michael J. Jacobs, MD
Academic Hospital Maastricht
Department of Vascular Surgery
PO Box 5800
6202 AZ Maastricht, The Netherlands
REFERENCE
1. Biglioli P, Spirito R, Porqueddu M, Agrifoglio M, Pompilio G, Parolari
A, et al. Quick, simple clamping technique in descending thoracic aortic
aneurysm repair. Ann Thorac Surg 1999;67:1038-43.
doi:10.1016/j.jvs.2009.05.002
Regarding “What a vascular surgeon should know
and do about atherosclerotic risk factors”
Liapis et al provide an excellent guide for the management of
the various conventional, conditional and emerging vascular risk
factors.1
A risk factor that may deserve more attention is hypertriglyc-
eridemia. Currently, hypertriglyceridemia is considered as a condi-tional risk factor.1 According to the AHA/ACC Guidelines,2 as
well as the recommendations of the authors,1 lowering triglyceride
levels 1.7 mmol/l (150 mg/dl) is a secondary target, whereas
lowering low-density lipoprotein cholesterol (LDL-C) levels2.6
mmol/l (100 mg/dl) is a primary target. However, if triglycer-
ides are 500 mg/dl, the treatment of LDL-C to goal becomes a
secondary target;2 triglyceride-lowering therapy should be initiated
immediately to prevent the development of acute pancreatitis.2
The importance of aiming at normal triglyceride levels to
prevent cardiovascular disease could already be extrapolated from a
study published more than three decades ago.3 This study evalu-
ated the presence of coronary artery disease and peripheral arterial
disease (PAD) in 280 patients with different types of primary
hyperlipoproteinemia. It was demonstrated that the prevalence of
PAD was much higher in patients with hypertriglyceridemia (21%
in Type IIb; 20% in Type V) than in subjects with hypercholester-
olemia alone (9% in Type IIa).3
In a nested case-control study, plasma samples were collected
at baseline from a prospective cohort of 14,916 initially healthy
individuals aged 40 to 84 years.4 During an average follow-up
period of nine years, 140 subjects developed PAD. Although the
total cholesterol/high-density lipoprotein cholesterol ratio was the
strongest predictor for the development of PAD (relative risk
[RR], 3.4; 95% confidence interval [CI], 1.7-7.0; P .001), high
triglyceride levels at baseline were an independent risk factor and
almost equally strong predictor (RR, 2.9; 95% CI, 1.4-5.8; P 
.001).4
Similarly, the Atherosclerosis Risk in Communities (ARIC)
Study assessed the relation of traditional and non-traditional risk
factors with the risk of PAD in 1,651 participants with diabetes,
but not PAD, at baseline.5 After a mean follow-up of 10.3 years,
the risk of developing PAD was increased 1.75-fold (95% CI:
1.18-2.60) for the highest versus the lowest quartile of triglycer-
ides.5 Surprisingly, no evidence was found of any association
between the development of PAD with other blood lipids or
hypertension.5
Hypercholesterolemia is indeed the strongest predictor of
cardiovascular disease and should thus comprise a primary thera-
peutic target.1,2,4 Nevertheless, hypertriglyceridemia should not
be viewed as a secondary therapeutic goal under all circumstances
(eg, when triglycerides500 mg/dl).2 Hypertriglyceridemia is an
important vascular risk factor, the management of which should
not be neglected. Given the association between hypertriglyceri-
demia, atherosclerosis, and cardiovascular risk,6 future guidelines
may need to consider hypertriglyceridemia as a conventional and
not a conditional risk factor.1
Kosmas I. Paraskevas, MD, FASA
Department of Vascular Surgery
Red Cross Hospital
Athens, Greece
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